ID

31474

Descrizione

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00944905

collegamento

https://clinicaltrials.gov/show/NCT00944905

Keywords

  1. 26/08/18 26/08/18 -
  2. 27/08/18 27/08/18 - Sarah Riepenhausen
Titolare del copyright

Bristol-Myers Squibb

Caricato su

27 agosto 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Renal Cell Carcinoma and B-Cell Non-Hodgkin's Lymphoma NCT00944905

Eligibility Renal Cell Carcinoma and B-Cell Non-Hodgkin's Lymphoma NCT00944905

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
eastern cooperative oncology group (ecog) performance status of 0 to 2
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
criteria specific for each tumor type: for clear cell renal cell carcinoma (ccrcc): advanced or recurrent disease. must have failed at least 1 prior systemic therapy
Descrizione

Advanced or recurrent clear cell renal cell carcinoma, prior therapy failed

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279702
UMLS CUI [1,2]
C0679246
UMLS CUI [1,3]
C1514463
UMLS CUI [1,4]
C0231175
UMLS CUI [2,1]
C0279702
UMLS CUI [2,2]
C0277556
UMLS CUI [2,3]
C1514463
UMLS CUI [2,4]
C0231175
criteria specific for each tumor type: for b-cell non-hodgkin's lymphoma (b-nhl): must have failed at least 1 prior systemic therapy
Descrizione

b-nhl with prior systemic therapy failed

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0024305
UMLS CUI [1,2]
C1514463
UMLS CUI [1,3]
C0231175
measurable disease criteria by tumor type: for ccrcc: at least 1 unidimensional measurable lesion
Descrizione

Clear cell renal cell carcinoma: measurable lesion

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279702
UMLS CUI [1,2]
C1513041
measurable disease criteria by tumor type: for b-nhl: at least 1 bidimensionally measurable lesion
Descrizione

B-nhl: measurable bidimensional lesion

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0024305
UMLS CUI [1,2]
C1513041
UMLS CUI [1,3]
C1705052
prior therapies for advanced/recurrent ccrcc or relapsed/refractory b-nhl or have become intolerant to a systemic therapy
Descrizione

Prior therapy for advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory b-nhl

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0279702
UMLS CUI [1,3]
C0679246
UMLS CUI [2,1]
C1514463
UMLS CUI [2,2]
C0279702
UMLS CUI [2,3]
C0277556
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C0855089
UMLS CUI [4,1]
C1514463
UMLS CUI [4,2]
C0855090
UMLS CUI [5,1]
C1744706
UMLS CUI [5,2]
C1515119
provide archived or fresh tumor tissue for cd70 status. subjects must be cd70+
Descrizione

CD70 antigen positive

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514241
UMLS CUI [1,2]
C0215991
provision of fresh tissue (pre-treatment and on-treatment) for exploratory analysis is mandatory for at least 5 and a maximum of 10 b-nhl subjects
Descrizione

Provision of fresh tumor tissue

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1292533
UMLS CUI [1,2]
C2827486
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior therapy with an anti-cd70 antibody
Descrizione

Prior therapy with an anti-cd70 antibody

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0281176
UMLS CUI [1,3]
C0215991
history of severe hypersensitivity reactions to other monoclonal antibodies
Descrizione

Hypersensitivity to monoclonal antibodies

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0003250
active or untreated central nervous system lymphoma
Descrizione

CNS lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0280803
active infection (viral, bacterial, or fungal)
Descrizione

Infection

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3714514
evidence of bleeding diathesis or coagulopathy
Descrizione

Bleeding diathesis or coagulopathy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005779
active autoimmune disease requiring immunosuppressive therapy
Descrizione

Concomitant autoimmune disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021079
UMLS CUI [1,2]
C0004364
known current drug or alcohol abuse
Descrizione

Substance abuse

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013146
UMLS CUI [2]
C0085762

Similar models

Eligibility Renal Cell Carcinoma and B-Cell Non-Hodgkin's Lymphoma NCT00944905

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
Advanced or recurrent clear cell renal cell carcinoma, prior therapy failed
Item
criteria specific for each tumor type: for clear cell renal cell carcinoma (ccrcc): advanced or recurrent disease. must have failed at least 1 prior systemic therapy
boolean
C0279702 (UMLS CUI [1,1])
C0679246 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C0231175 (UMLS CUI [1,4])
C0279702 (UMLS CUI [2,1])
C0277556 (UMLS CUI [2,2])
C1514463 (UMLS CUI [2,3])
C0231175 (UMLS CUI [2,4])
b-nhl with prior systemic therapy failed
Item
criteria specific for each tumor type: for b-cell non-hodgkin's lymphoma (b-nhl): must have failed at least 1 prior systemic therapy
boolean
C0024305 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
Clear cell renal cell carcinoma: measurable lesion
Item
measurable disease criteria by tumor type: for ccrcc: at least 1 unidimensional measurable lesion
boolean
C0279702 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
B-nhl: measurable bidimensional lesion
Item
measurable disease criteria by tumor type: for b-nhl: at least 1 bidimensionally measurable lesion
boolean
C0024305 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C1705052 (UMLS CUI [1,3])
Prior therapy for advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory b-nhl
Item
prior therapies for advanced/recurrent ccrcc or relapsed/refractory b-nhl or have become intolerant to a systemic therapy
boolean
C1514463 (UMLS CUI [1,1])
C0279702 (UMLS CUI [1,2])
C0679246 (UMLS CUI [1,3])
C1514463 (UMLS CUI [2,1])
C0279702 (UMLS CUI [2,2])
C0277556 (UMLS CUI [2,3])
C1514463 (UMLS CUI [3,1])
C0855089 (UMLS CUI [3,2])
C1514463 (UMLS CUI [4,1])
C0855090 (UMLS CUI [4,2])
C1744706 (UMLS CUI [5,1])
C1515119 (UMLS CUI [5,2])
CD70 antigen positive
Item
provide archived or fresh tumor tissue for cd70 status. subjects must be cd70+
boolean
C1514241 (UMLS CUI [1,1])
C0215991 (UMLS CUI [1,2])
Provision of fresh tumor tissue
Item
provision of fresh tissue (pre-treatment and on-treatment) for exploratory analysis is mandatory for at least 5 and a maximum of 10 b-nhl subjects
boolean
C1292533 (UMLS CUI [1,1])
C2827486 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Prior therapy with an anti-cd70 antibody
Item
prior therapy with an anti-cd70 antibody
boolean
C1514463 (UMLS CUI [1,1])
C0281176 (UMLS CUI [1,2])
C0215991 (UMLS CUI [1,3])
Hypersensitivity to monoclonal antibodies
Item
history of severe hypersensitivity reactions to other monoclonal antibodies
boolean
C0020517 (UMLS CUI [1,1])
C0003250 (UMLS CUI [1,2])
CNS lymphoma
Item
active or untreated central nervous system lymphoma
boolean
C0280803 (UMLS CUI [1])
Infection
Item
active infection (viral, bacterial, or fungal)
boolean
C3714514 (UMLS CUI [1])
Bleeding diathesis or coagulopathy
Item
evidence of bleeding diathesis or coagulopathy
boolean
C0005779 (UMLS CUI [1])
Concomitant autoimmune disease
Item
active autoimmune disease requiring immunosuppressive therapy
boolean
C0021079 (UMLS CUI [1,1])
C0004364 (UMLS CUI [1,2])
Substance abuse
Item
known current drug or alcohol abuse
boolean
C0013146 (UMLS CUI [1])
C0085762 (UMLS CUI [2])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial